Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - Viridian Therapeutics, Inc.\DE | v372626_s1a.htm |
| EX-10.11 - EXHIBIT 10.11 - Viridian Therapeutics, Inc.\DE | v372626_ex10-11.htm |
| EX-5.1 - EXHIBIT 5.1 - Viridian Therapeutics, Inc.\DE | v372626_ex5-1.htm |
| EX-10.20 - EXHIBIT 10.20 - Viridian Therapeutics, Inc.\DE | v372626_ex10-20.htm |
| EX-10.15 - EXHIBIT 10.15 - Viridian Therapeutics, Inc.\DE | v372626_ex10-15.htm |
| EX-10.17 - EXHIBIT 10.17 - Viridian Therapeutics, Inc.\DE | v372626_ex10-17.htm |
| EX-10.16 - EXHIBIT 10.16 - Viridian Therapeutics, Inc.\DE | v372626_ex10-16.htm |
| EX-10.19 - EXHIBIT 10.19 - Viridian Therapeutics, Inc.\DE | v372626_ex10-19.htm |
| EX-10.2 - EXHIBIT 10.2 - Viridian Therapeutics, Inc.\DE | v372626_ex10-2.htm |
| EX-10.18 - EXHIBIT 10.18 - Viridian Therapeutics, Inc.\DE | v372626_ex10-18.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Signal Genetics LLC
New York, New York
We hereby consent to the use in the Prospectus constituting a part of this Amendment No. 1 to Registration Statement of our report dated March 18, 2014 relating to the financial statements of Signal Genetics LLC, which is contained in that Prospectus. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
| New York, New York | |
| April 9, 2014 |